These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25287191)

  • 41. Codon optimization of human factor VIII cDNAs leads to high-level expression.
    Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
    Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
    Xu L; Mei M; Ma X; Ponder KP
    J Thromb Haemost; 2007 Sep; 5(9):1805-12. PubMed ID: 17596134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.
    Baumgartner CK; Zhang G; Kuether EL; Weiler H; Shi Q; Montgomery RR
    J Thromb Haemost; 2015 Dec; 13(12):2210-9. PubMed ID: 26453193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo.
    Zhang W; Mao J; Shen Y; Zhang G; Shao Y; Ruan Z; Wang Y; Wu W; Wang X; Zhu J; Chen S; Xiao W; Xi X
    Blood Cells Mol Dis; 2018 Nov; 73():47-54. PubMed ID: 30249384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
    Chen Y; Schroeder JA; Chen J; Luo X; Baumgartner CK; Montgomery RR; Hu J; Shi Q
    Blood; 2016 Mar; 127(10):1346-54. PubMed ID: 26668132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
    Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
    Evans GL; Morgan RA
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.
    Wang Y; Mao J; Li L; Xiao B; Ruan Z; Liu Y; Zhang G; Wang D; Mi JQ; Fang C; Xi X; Shi X; Wang J
    Thromb Haemost; 2022 May; 122(5):755-766. PubMed ID: 34587639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A.
    Johnston JM; Denning G; Doering CB; Spencer HT
    Gene Ther; 2013 Jun; 20(6):607-15. PubMed ID: 22996197
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.
    Cao W; Sabatino DE; Altynova E; Lange AM; Casina VC; Camire RM; Zheng XL
    J Biol Chem; 2012 Sep; 287(39):32459-66. PubMed ID: 22854959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delivery of factor VIII gene into skeletal muscle cells using lentiviral vector.
    Jeon HJ; Oh TK; Kim OH; Kim ST
    Yonsei Med J; 2010 Jan; 51(1):52-7. PubMed ID: 20046514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
    Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
    Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648.
    Chiang GG; Rubin HL; Cherington V; Wang T; Sobolewski J; McGrath CA; Gaffney A; Emami S; Sarver N; Levine PH; Greenberger JS; Hurwitz DR
    Hum Gene Ther; 1999 Jan; 10(1):61-76. PubMed ID: 10022531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biosynthesis of FVIII in megakaryocytic cells: improved production and biochemical characterization.
    Rodriguez MH; Plantier JL; Enjolras N; Réa M; Leboeuf M; Uzan G; Négrier C
    Br J Haematol; 2004 Dec; 127(5):568-75. PubMed ID: 15566360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
    Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
    Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An induced pluripotent stem cell-mediated and integration-free factor VIII expression system.
    Yakura Y; Ishihara C; Kurosaki H; Kazuki Y; Komatsu N; Okada Y; Doi T; Takeya H; Oshimura M
    Biochem Biophys Res Commun; 2013 Feb; 431(2):336-41. PubMed ID: 23291180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
    Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stable expression of native Coagulation factor VIII using the 2A self-processing sequence and furin cleavage site.
    He B; Pan Y; Chen L; Xu Y; Chen N; Gu L; Nie Z; Wang S; Liu Z
    Thromb Res; 2011 Dec; 128(6):e148-53. PubMed ID: 21803400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.